Group 1 - The core viewpoint of the news is the online launch of the innovative oral antiviral drug, Mapasavir Capsules (brand name: Yilikang®), by Health元药业集团 on JD Health platform, aimed at providing a new treatment option for influenza [1][3]. - Influenza, caused by the influenza virus, poses a significant health threat, especially to vulnerable populations such as children, the elderly, and those with chronic diseases, necessitating timely antiviral treatment to mitigate risks [3]. - Mapasavir Capsules utilize a novel mechanism as a cap-dependent endonuclease inhibitor, effectively blocking the replication of the influenza virus at an early stage, offering broad-spectrum antiviral activity against both type A and B influenza viruses [3]. Group 2 - Health元药业集团 is an innovative pharmaceutical group focused on unmet clinical needs, with over 20 first-class innovative drugs in its portfolio, more than 10 of which are in critical phases of development [4]. - The online launch of Yilikang® marks the beginning of a deeper collaboration between Health元 and JD Health, leveraging JD Health's marketing resources and supply chain to enhance patient access to the drug [4]. - Future collaborations will focus on comprehensive influenza prevention and treatment, including improving drug accessibility, patient education, and influenza warning systems, aiming to create an integrated health service ecosystem [4].

Core Insights - JD Health and Nanchang University First Affiliated Hospital have signed a strategic cooperation framework agreement to leverage opportunities in "Artificial Intelligence + Healthcare" [1][3] - The collaboration aims to enhance patient service experience and hospital operational capabilities through the integration of JD Health's "JD Zhuoyi" large model product [1][3] Group 1: Strategic Collaboration - The partnership will create an integrated patient service entry point covering pre-diagnosis, diagnosis, and post-diagnosis processes, improving patient experience [3] - A comprehensive nutrition management system will be established, forming a closed-loop management system from risk screening to clinical intervention and consumer conversion [3] Group 2: Technological Integration - JD Health will utilize its e-commerce platform, pharmaceutical supply chain, logistics, and digital marketing capabilities to support the hospital's internal products and services [4] - The collaboration will also establish a convenient health service platform that includes online health services and offline self-service vending machines to meet patient needs throughout their healthcare journey [4] Group 3: Industry Impact - The strategic cooperation is seen as a significant step in applying "Artificial Intelligence + Healthcare" in practice, setting a benchmark for the industry [4] - JD Health aims to continuously enhance patient medical experience and contribute to the high-quality development of the healthcare industry through innovative products and services [4]

近日，京东健康与南昌大学第一附属医院(以下简称"南大一附院")正式签署战略合作框架协议。双方将 把握"人工智能+医疗健康"发展机遇，依托京东健康面向医院全场景打造的大模型产品"京东卓医"，以 一体化管理为基础、以优质医疗资源下沉共享为核心，助力南大一附院构建以患者为核心、线上线下全 流程一体化的医疗服务新模式，切实提升患者服务体验。 作为全国首批三级甲等医院，南大一附院承担着江西省重大公共卫生事件医学中心、国家重大疫情防控 救治基地等重要职能，在医疗资源配置、临床诊疗能力和行业影响力方面具备雄厚实力。作为行业领先 的新型医疗健康服务机构，京东健康依托"京东卓医"大模型产品，助力多家线下医疗机构提供更加高 效、普惠、智能的医疗健康服务。此次双方的战略合作，正是响应国家政策导向、顺应行业发展趋势的 重要实践。 根据合作协议，双方将基于"京东卓医"大模型产品，共同构建一体化患者服务主入口，覆盖诊前、诊 中、诊后全流程场景，提升患者服务体验与医院经营能力。双方将合作建立营养全程管理体系，构 建"筛-评-诊-治-管"临床营养一体化系统，形成"风险筛查-临床干预-消费转化"闭环管理。同时，整合南 大一附院检验科专业能力和 ...

近年来，中医药滋补养生市场持续扩容。其中，六味地黄类产品作为滋阴补肾的经典品类，市场需求潜 力巨大。与此同时，传统剂型正加速向更便捷、更适口的方向创新，膏滋、口服液等新剂型日益受到当 代快节奏生活人群的青睐。华润江中敏锐洞察这一趋势，将传承千年的经典名方与现代剂型创新相结 合，为滋阴补肾市场带来一款易于服用、方便携带、高效吸收的膏滋新品，满足现代消费者对高效、便 捷、品质滋补的新需求。 12月25日，华润江中旗下六味地黄膏在京东健康首发上线，消费者即日起登录京东APP搜索"江中六味 地黄膏"即可咨询与购买，开启轻松、便捷的滋补调理新体验。 作为国民信赖的健康品牌，华润江中始于1969年，是一家集医药研发、生产与销售于一体的国有大型企 业，旗下"江中"品牌价值超466亿元，已连续22年入选中国500最具价值品牌。其位于南昌的江中药谷制 造基地，是国家级绿色工厂与智能制造的典范。2023年，华润江中牵头获批"经典名方现代中药创制全 国重点实验室"，依托4个国家级及8个省部级研发平台，构建了从药材源头到产品出厂的全链条质量管 控体系，为六味地黄膏等产品的卓越品质保驾护航。 本次新品发布是双方深度合作的又一重要里程碑 ...

Core Insights - JD Health and Love Health signed a strategic cooperation agreement for 2026, aiming to enhance collaboration in the healthcare supply chain, digital marketing innovation, user service experience, and project incubation in the sexual health industry [1][3] Group 1: Strategic Partnership - The partnership focuses on "co-building high growth" by leveraging resource advantages to drive the sexual health industry towards professionalism and digitization [1] - JD Health has become the launch platform for new strategic products from Love Health, indicating a strong collaborative relationship [3] Group 2: Marketing and Product Performance - Since 2025, both companies have engaged in deep marketing cooperation, utilizing a "breakthrough products + scenario penetration" model to stimulate consumer enthusiasm and expand brand presence [3] - The Durex brand, under Love Health, launched the Durex Super Thin 003 delay condom on JD's platform, achieving over 10 million sales within a month, setting an industry benchmark [3] - In the lubricant category, Durex leads with a comprehensive medical product line, with hyaluronic acid lubricants seeing over 20% year-on-year growth and female pleasure liquids growing over 30%, meeting market demand for safe and comfortable health products [3] - Durex's delay spray and wet wipes also demonstrated strong market competitiveness, with a 95% year-on-year increase in sales, gaining consumer favor [3] Group 3: Future Directions - The signing of the strategic cooperation agreement marks a significant milestone for both companies, with plans to continue driving product innovation and exploring the integration of smart technology in health and lifestyle [3]

Core Insights - The silver-haired demographic is emerging as a significant force in China's health economy by 2025, shifting from a focus on basic needs to a desire for enhanced quality of life and smart consumption [1][2] Group 1: Changing Consumption Patterns - Over 60% of the new silver-haired group have raised their quality of life expectations post-retirement, moving from a focus on low-cost practicality to a preference for quality and smart solutions [1] - The trend of purchasing health-related products online is growing, with e-commerce platforms becoming key channels for the silver-haired population to buy various medications and health products [2][3] Group 2: Increased Demand for Professional Health Services - There is a rising demand for professional health services among the elderly, as evidenced by cases of individuals being misled in online purchases, highlighting the need for transparent and reliable health guidance [6][7] - The introduction of AI doctors, pharmacists, and nutritionists has significantly lowered the barriers for elderly users to seek health consultations, with a notable increase in user engagement during late hours [9][10] Group 3: Technological Integration in Health Management - The integration of AI and smart health products is transforming elderly care, with products like dynamic blood glucose monitors showing significant sales growth, indicating a shift towards proactive health management [10][12] - Companies like JD Health are evolving from mere product sales to comprehensive health management solutions, aiming to serve the deep health management needs of the silver-haired population [12][13]

在企业分享环节，广东合一云康医药有限公司负责人肖子雄重点介绍了儿童补锌专用品牌巨可生的发展 路径与生态共建思路。肖子雄表示，巨可生深耕儿童补锌领域，以"专业、安全、精准"为核心，打造了 以赖氨葡锌颗粒(无糖)为核心的明星产品，精准匹配儿童生长发育阶段的营养需求。为了让更多家庭受 2025年12月16日，以"童心'药'健康，科普伴成长"为主题的京东健康儿科生态大会在北京顺利举行。本 次大会汇聚了首都医科大学附属北京儿童医院、北京大学人民医院等国内顶级医疗机构的名医专家，以 及达因药业集团、广东合一云康医药等知名药企代表，围绕儿童健康领域的热点议题展开深度交流。作 为儿童补锌专用品牌的核心代表，巨可生受邀参与大会，并与小葵花、哈药、伊可新等二十余家知名健 康品牌共同加入京东健康儿科生态伙伴联盟，携手为儿童健康保驾护航。 大会现场，名医专家们针对儿童呼吸道疾病、癫痫诊疗、心理健康、婴幼儿成长等关键话题分享了专业 见解。 中国儿科神经病学专家、北京大学人民医院儿科教授秦炯指出，儿童健康保障需依托"医、药、险、 教、家"多方联动，破解行业痛点；首都医科大学附属北京回龙观医院精神医学研究中心主任谭淑平则 强调，儿童身心健 ...

Core Insights - JD Health and H&H Group have signed a strategic cooperation agreement aiming for a combined business target of 10 billion yuan over the next three years, marking an upgrade to a comprehensive and deep strategic partnership after ten years of close collaboration [1][2] Group 1: Partnership Details - The partnership will focus on enhancing supply chain efficiency, user health management, and data-driven innovation, leveraging JD Health's integrated sales and supply chain capabilities to effectively reach target users for H&H Group's diverse nutrition product lines [2] - H&H Group's CEO, Li Fengting, emphasized the importance of JD Health as a key partner in the Chinese market, aiming to integrate global quality nutrition resources with JD Health's digital technology and user insights [2] Group 2: Market Context - The collaboration comes amid a backdrop of continuous upgrades in health consumption, aiming to drive the health industry towards a more professional, systematic, and personalized development phase, providing richer health products and more convenient shopping experiences for Chinese families [3]

针对黄褐斑易复发的痛点，孚立美®在8周标准治疗后可采用梯度维持方案：第9周至12周隔天一 次，第13周至16周每周两次，第17周至20周每周一次，有效降低复发风险，让祛斑效果更持久。 目前，孚立美®已在京东健康正式开启独家预约，用户可通过京东APP搜索"孚立美"，在线咨询专 业医师后完成处方开具与购买，足不出户即可获得规范治疗方案。针对首次预约用户，还可享受医师一 对一用药指导、全程疗效跟踪等专属服务，让科学祛斑更省心、更安心。 （编辑 郭之宸） 本报讯 （记者梁傲男）12月25日，孚诺医药旗下新药孚立美®氟轻松氢醌维A酸乳膏在京东健康开 启独家预约，为中重度黄褐斑患者带来科学祛斑新方案。用户通过京东APP搜索"孚立美"即可预约。 黄褐斑的发病与遗传、日光照射、激素变化密切相关，尤其多见于30-39岁育龄女性、妊娠后女 性、长期日晒或熬夜的职场人群。孚立美®适用于在防晒措施下，对面部中、重度黄褐斑的短期治疗， 无论是活动期的基础治疗，还是稳定期联合光电治疗的辅助方案，均被《中国黄褐斑诊疗专家共识 （2021版）》推荐为一线用药。 作为国内首款获批的Kligman配方制剂，孚立美®配方包含0.01%氟轻松、4% ...

本报讯(记者梁傲男)12月25日，孚诺医药旗下新药孚立美氟轻松氢醌维A酸乳膏在京东健康开启独家预 约，为中重度黄褐斑患者带来科学祛斑新方案。用户通过京东APP搜索"孚立美"即可预约。 黄褐斑的发病与遗传、日光照射、激素变化密切相关，尤其多见于30-39岁育龄女性、妊娠后女性、长 期日晒或熬夜的职场人群。孚立美适用于在防晒措施下，对面部中、重度黄褐斑的短期治疗，无论是活 动期的基础治疗，还是稳定期联合光电（300691）治疗的辅助方案，均被《中国黄褐斑诊疗专家共识 (2021版)》推荐为一线用药。 作为国内首款获批的Kligman配方制剂，孚立美配方包含0.01%氟轻松、4%氢醌、0.05%维A酸三种精准 配比的活性成分，三者协同发力：氢醌强效阻断黑素生成，维A酸加速色素脱落并促进药物渗透，氟轻 松则减轻皮肤刺激、稳定皮肤状态。 针对黄褐斑易复发的痛点，孚立美在8周标准治疗后可采用梯度维持方案：第9周至12周隔天一次，第13 周至16周每周两次，第17周至20周每周一次，有效降低复发风险，让祛斑效果更持久。 目前，孚立美已在京东健康正式开启独家预约，用户可通过京东APP搜索"孚立美"，在线咨询专业医师 后完成处 ...